Sign in
Taking people in United StatesNo phase

Testing mitoquinone for long-term effects of COVID-19 in adults

Tests the supplement mitoquinone against placebo in adults recovering from COVID-19.

Key facts

Who runs it
VA Office of Research and Development
Where
Salt Lake City, United StatesSee the site
Trial code
Registry title
Long-term COVID and Rehabilitation
Status
Recruiting
People taking part
300 people, planned
Started
1 Nov 2022
Expected to end
31 Oct 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Mitoquinone
  • Placebo
Record updated
30 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who had COVID-19 3 to 12 months ago, including people with long-COVID, to test rehabilitation and a supplement for blood vessel health.

Age
18 years and older
Sex
All sexes can join.
Disease stage
Long-COVID, or recovered from COVID-19, 3 to 12 months after the first COVID-19 diagnosis.
Earlier treatment
People already taking Mito-Q, or unwilling to stop dietary supplements, cannot join.
Biomarker or test result
A positive SARS-CoV-19 test near the time of the COVID-19 diagnosis.

Main reasons for not taking part

  • BMI above 45 kg/m2
  • Severe or unstable heart, artery, brain blood vessel or lung disease, or uncontrolled high blood pressure
  • Kidney disease needing dialysis or severe kidney problems
  • Alzheimer's disease or dementia
  • Current smokers, or people who stopped smoking in the last 10 years

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Long-COVID and COVID-recovered patients must have SARS-CoV-19 positive test near the time of COVID-19 diagnosis
  • Long-COVID and COVID-recovered patients must be 3-12 months post-initial COVID-19 diagnosis
  • Ability to sign informed consent

Who cannot take part

  • Any other condition or event considered exclusionary by the PIs or a physician
  • Unstable (<6 months) or severe coronary artery disease (CAD-RADS score = 4A), peripheral artery disease (Ankle Brachial Index <0.40), cerebrovascular disease (identified by previous stroke in last 12 months), severe COPD (=Stage III), uncontrolled hypertension (>160/100 mmHg), chronic kidney disease requiring dialysis, severe renal insufficiency (creatinine clearance <30 by the Cockcroft-Gault formula), Alzheimer's disease, dementia
  • BMI >45 kg/m2
  • Orthopedic limitations that would prohibit exercise
  • Current smokers and individuals that stopped smoking in the last 10 years
  • Already taking Mito-Q or unwilling to cease dietary supplements for participation

This trial is currently available in United States.

  • VA Salt Lake City Health Care System, Salt Lake City, UTSalt Lake City, United StatesContact: P Jon White, MDTaking people

About the trial

What the trial wants to find out

The proposed focuses on improving both morbidity and mortality in older Veterans and those recovering from COVID-19 by developing rehabilitation therapies to augment vascular endothelial function by combating the oxidative stress and inflammation associated with aging and further induced by COVID-19. The investigators expected outcomes will have an important positive impact because they will provide scientifically sound recommendations for rehabilitation to improve vascular endothelial function and minimize the long-term consequences of COVID-19.

The 2 groups in the trial

  • Exercise RehabilitationTreatment being tested

    Participants will be assigned to the Exercise+Placebo or Exercise+Mito-Q rehabilitation interventions using block randomization (block size 10).

    Treatment: Mitoquinone

  • Exercise Rehabilitation with PlaceboPlacebo, for comparison

    Participants will be assigned to Exercise+Placebo rehabilitation using block randomization (block size 10)

    Treatment: Mitoquinone and Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluating the Long-term Health Consequences of COVID-19 and Rehabilitation Therapies to Speed Convalescence
Plain-language title
Testing mitoquinone for long-term effects of COVID-19 in adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
30 July 2026